Cuer J C, Dapoigny M, Bommelaer G
Service d'Hépato Gastro Entérologie, Clermont-Ferrand, France.
Endoscopy. 1993 Aug;25(6):384-6. doi: 10.1055/s-2007-1010345.
Midazolam, a water-soluble benzodiazepine, has recently been introduced and found to be beneficial for sedation in upper GI endoscopy. Whereas it has been proven that diazepam does not have any effect on sphincter of Oddi (SO) motility in humans, no respective data exist on midazolam. On evaluation of the possible effects of midazolam on SO motility recording by means of endoscopic manometry, we found that midazolam had no effect on basal pressure (24.2 +/- 12.59 mm Hg before and 23.85 +/- 12.63 mm Hg after midazolam, p = 0.55), amplitude (39.75 +/- 22.62 versus 44.55 +/- 27.15, p = 0.097), duration (4.9 +/- 1.8 sec versus 5.05 +/- 1.7 sec, p = 0.614), and frequency of SO contractions (7.75 +/- 1.68 waves/min versus 7.15 +/- 1.92 waves/min, p = 0.083). These results suggest that in patients with normal manometric findings midazolam does not interfere with SO recording.
咪达唑仑是一种水溶性苯二氮䓬类药物，最近已被引入并发现对在上消化道内镜检查中进行镇静有益。虽然已证实地西泮对人体的Oddi括约肌（SO）运动没有任何影响，但关于咪达唑仑尚无相关数据。通过内镜测压评估咪达唑仑对SO运动记录的可能影响时，我们发现咪达唑仑对基础压力（咪达唑仑前为24.2±12.59 mmHg，咪达唑仑后为23.85±12.63 mmHg，p = 0.55）、幅度（39.75±22.62对44.55±27.15，p = 0.097）、持续时间（4.9±1.8秒对5.05±1.7秒，p = 0.614）以及SO收缩频率（7.75±1.68次/分钟对7.15±1.92次/分钟，p = 0.083）均无影响。这些结果表明，在内镜测压结果正常的患者中，咪达唑仑不会干扰SO记录。
